As shown in Table 3a, there were no statistically significant differences in 14-day and 30-day all-cause mortality rates, clinical resolution, or adverse effects, including PT prolongation, CDAD, diarrhea, leukopenia, and neutropenia, between the two groups with bacteremia due to MDROs, although the mortality rate seemed to be higher in the CFP–SUL 2 g/2 g group without reaching statistical significance. This evidence concerns the gene CFP and Decreased total neutrophil count.